Autonomix Medical Strengthens Global Intellectual Property Position with New Neural Sensing Patent Grant

About this update from Autonomix Medical, Inc.

 IP portfolio reflects Autonomix's neural sensing leadership in multi-billion-dollar denervation market Technical highlights on newly issued patent include real-time nerve monitoring and diagnostic evaluation THE WOODLANDS, TX, July 13, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it has been granted Canadian Patent No. 3,158,197, titled " Endoscopic Sympathectomy Systems and Methods ." The Company's growing global intellectual property portfolio now includes 112 issued or pending patent applications worldwide with the newest patent further strengthening the Company's intellectual property position across multiple nerve-targeted therapies and denervation applications. The newly issued patent expands and reinforces Autonomix's intellectual property estate related to real-time nerve sensing, mapping, physiological monitoring, and feedback-guided neuromodulation technologies. The patented systems and methods are designed to enable more precise targeting of autonomic nerves associated with a variety of chronic disease states, including hypertension, chronic heart failure, chronic renal failure, metabolic disorders, and other conditions linked to autonomic nervous system dysfunction and renal sympathetic nerve hyperactivity. Unlike conventional denervation approaches that rely primarily on anatomical landmarks, the patented technology incorporates sensing-enabled devices capable of detecting neural and physiological responses in real time. This closed-loop approach may enable physicians to locate neural targets more accurately, assess treatment effects during therapy delivery, and evaluate procedural success through objective physiological feedback. Corresponding patents covering related inventions have previously been issued in the United States and Europe, reinforcing Autonomix's intellectual property position across major commercial markets. "Securing this Canadian patent further strengthens our competitive position and expands the intellectual property foundation supporting our precision neuromodulation platform," said Brad Hauser, Chief Executive Officer of Autonomix. "We believe the ability to identify, monitor and modulate neural targets using real-time physiological feedback may represent a transformational advancement in nerve-targeted therapy. This patent not only reinforces our technological differentiation but also supports our vision of expanding the platform across multiple large clinical markets where improved treatment precision may lead to better patient outcomes."

View stock analysis, news, and events for Autonomix Medical, Inc.